Physician profile
Omar M Murad
NPI 1598738015
$3,986.32
in general payments reported to CMS, 2019-2025
20 companies · $1,707 in 2025
The $1,707 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2021: $455 · 2022: $867 · 2023: $428 · 2024: $294 · 2025: $1,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,379 · Entertainment: $50.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,378.91 |
| Entertainment | $50.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,311.30 | 2021-2025 | Ozempic, Rybelsus, Sogroya |
| Ascendis Pharma Endocrinology INC | $272.13 | 2025 | Yorvipath |
| Amgen INC. | $256.37 | 2019-2025 | Evenity, Tepezza |
| Dexcom, INC. | $189.44 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $182.07 | 2019-2025 | Zepbound, Mounjaro |
| Beta Bionics, INC. | $134.53 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Grt US Holding, INC. | $125.00 | 2022 | |
| Tandem Diabetes Care, INC. | $84.38 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $82.02 | 2021-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.93 | 2025 | Jardiance |
| Optos, INC. | $50.31 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Intuitive Surgical, INC. | $47.86 | 2022 | |
| Madrigal Pharmaceuticals | $45.62 | 2025 | Rezdiffra |
| Insulet Corporation | $25.00 | 2023 | Omnipod |
| Pacira Pharmaceuticals Incorporated | $22.00 | 2025 | Exparel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $19.79 | 2019 | |
| Abbott Laboratories | $19.77 | 2021 | |
| Cequr Corporation | $17.41 | 2023 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $15.26 | 2021 | |
| Bigfoot Biomedical INC | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Murad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.